Allogeneic bone marrow-derived mesenchymal stem cells therapy (Corestemchemon)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAllogeneic bone marrow-derived mesenchymal stem cells therapy (Corestemchemon)

Drug Alias NameCE211NS21

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsUpdating

Therapy Area/IndicationsNeuromyelitis Optica

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCorestemchemon Inc

China Registration ClassN/A

Develop Information

Active CompaniesCorestemchemon Inc

Inactive CompaniesN/A

Active IndicationsNeuromyelitis Optica

Inactive IndicationsN/A

Other Information

ATC CodeN/A